A Phase ll of Rituximab in Myasthenia Gravis (NN 103)

Grant

Date/time Interval

  • April 21, 2015 - June 30, 2023
  • Total Award Amount

  • 16536.00
  • Direct Costs

  • 11249.00
  • Sponsor Award Id

  • NN 103
  • Contributor

  • Ubogu, Eroboghene   Principal Investigator